May Health is developing Ovarian Rebalancing™, a one-time outpatient treatment that utilizes targeted ovarian ablation to lower androgen production and restore ovulation in individuals with Polycystic Ovary Syndrome (PCOS) related infertility. Currently in clinical trials, this investigational treatment aims to provide a hormone-free solution for those struggling with ovulatory dysfunction due to PCOS.
Funding
$24.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TIFounders
Product
Problem
Polycystic Ovary Syndrome (PCOS) related infertility is often linked to high androgen levels and ovulatory dysfunction. Current treatments may involve hormone therapies, which can have undesirable side effects for some individuals. Managing PCOS-related infertility requires solutions that directly address the hormonal imbalances contributing to the condition.
Solution
May Health is developing Ovarian Rebalancing™, an investigational, one-time outpatient treatment designed to restore ovulation in individuals with PCOS-related infertility. The procedure utilizes targeted ovarian ablation to lower androgen production, addressing a key hormonal factor contributing to ovulatory dysfunction. By reducing androgen levels, Ovarian Rebalancing™ aims to provide a hormone-free alternative for those seeking to restore ovulation and improve their chances of conception. The treatment is currently undergoing clinical trials to validate its safety and effectiveness.
Target Audience
The primary target audience is individuals with PCOS-related infertility who are seeking a hormone-free solution to restore ovulation.
Features
- Targeted ovarian ablation to reduce androgen production
- Designed as a one-time outpatient procedure
- Aims to restore ovulation without hormone therapy
- Currently undergoing clinical trials to assess safety and efficacy